— Why it moved
Why LABT Stock Spiked and Faded Today — September 28, 2026
Lakewood-Amedex Biotherapeutics pushed out in vitro lab data for its diabetic foot ulcer gel, but the tiny float couldn't sustain the premarket pop before dumping hard.
What moved LABT stock
Lakewood-Amedex Biotherapeutics is a clinical-stage biotech developing topical antimicrobial treatments. The company released positive test-tube data showing their gel candidate worked against drug-resistant bacteria. It wasn't a human trial win, just lab culture results, but day traders scrambled for the headline anyway.
The mechanics
A tight float of 1.02 million shares on a sub-four-million-dollar market cap created an instant liquidity squeeze. Over 35 million shares rotated through the tape during the session, making the inevitable crash aggressive once the early buying dried up.
LABT by the numbers
The alert window
The alert hit at 8:10 AM at $3.24. It pushed to a peak of $3.77 in three minutes, offering a quick 16.3% sellable window before falling to a $3.02 low. Price spent a grand total of five minutes above the alert level before dropping like a stone.
How LABT's move ended
It was a absolute trap by the afternoon. LABT closed at $1.13, a brutal 65.2% loss from the alert price. An effective S-1 registration statement went live late last week, giving the company a fresh green light to sell shares into heavy volume spikes like this one.
The tell: Early premarket spikes on basic lab data usually exist for one reason: allowing dilutive issuers to unload paper into retail volume.